{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:29:44Z","timestamp":1777501784046,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40256-020-00427-9","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T01:02:39Z","timestamp":1597194159000},"page":"219-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Optimal Medical Therapy Prescription in Patients with Acute Coronary Syndrome in the Netherlands: A Multicenter Pilot Registry"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9445-2483","authenticated-orcid":false,"given":"Niels P. G.","family":"Hoedemaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbert J.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnoud van\u2019t","family":"Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien","family":"Kolkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Damman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"issue":"42","key":"427_CR1","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1093\/eurheartj\/ehy554","volume":"39","author":"K Szummer","year":"2018","unstructured":"Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J. 2018;39(42):3766\u201376.","journal-title":"Eur Heart J."},{"issue":"41","key":"427_CR2","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1093\/eurheartj\/ehx515","volume":"38","author":"K Szummer","year":"2017","unstructured":"Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995\u20132014. Eur Heart J. 2017;38(41):3056\u201365.","journal-title":"Eur Heart J."},{"issue":"3","key":"427_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267\u2013315.","journal-title":"Eur Heart J."},{"issue":"20","key":"427_CR4","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Task Force on the management of STseamiotESoC, Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J."},{"issue":"3","key":"427_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213\u201360.","journal-title":"Eur Heart J."},{"key":"427_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2147\/CLEP.S99475","volume":"8","author":"C Ozcan","year":"2016","unstructured":"Ozcan C, Juel K, Flensted Lassen J, von Kappelgaard LM, Mortensen PE, Gislason G. The Danish Heart Registry. Clin Epidemiol. 2016;8:503\u20138.","journal-title":"Clin Epidemiol."},{"issue":"20","key":"427_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","volume":"96","author":"T Jernberg","year":"2010","unstructured":"Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, et al. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96(20):1617\u201321.","journal-title":"Heart."},{"issue":"13","key":"427_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/eurheartj\/ehx008","volume":"38","author":"O Bebb","year":"2017","unstructured":"Bebb O, Hall M, Fox KAA, Dondo TB, Timmis A, Bueno H, et al. Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP) register. Eur Heart J. 2017;38(13):974\u201382.","journal-title":"Eur Heart J."},{"issue":"4","key":"427_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12471-017-0947-6","volume":"25","author":"NP Hoedemaker","year":"2017","unstructured":"Hoedemaker NP, Ten Haaf ME, Maas JC, Damman P, Appelman Y, Tijssen JG, et al. Practice of ST-segment elevation myocardial infarction care in the Netherlands during four snapshot weeks with the National Cardiovascular Database Registry for Acute Coronary Syndrome. Neth Heart J. 2017;25(4):264\u201370.","journal-title":"Neth Heart J."},{"issue":"20","key":"427_CR10","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","volume":"33","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551\u201367.","journal-title":"Eur Heart J."},{"issue":"2","key":"427_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/ehjcvp\/pvy005","volume":"4","author":"NPG Hoedemaker","year":"2018","unstructured":"Hoedemaker NPG, Damman P, Ottervanger JP, Dambrink JHE, Gosselink ATM, Kedhi E, et al. Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting. Eur Heart J Cardiovasc Pharmacother. 2018;4(2):102\u201310.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"2","key":"427_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/2047487317744363","volume":"25","author":"DC Eindhoven","year":"2018","unstructured":"Eindhoven DC, Hilt AD, Zwaan TC, Schalij MJ, Borleffs CJW. Age and gender differences in medical adherence after myocardial infarction: women do not receive optimal treatment\u2014The Netherlands claims database. Eur J Prev Cardiol. 2018;25(2):181\u20139.","journal-title":"Eur J Prev Cardiol."},{"issue":"16","key":"427_CR13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509\u201324.","journal-title":"N Engl J Med."},{"issue":"5","key":"427_CR14","first-page":"485","volume":"378","author":"CP Cannon","year":"2018","unstructured":"Cannon CP, Lip GYH, Oldgren J. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2018;378(5):485\u20136.","journal-title":"N Engl J Med."},{"issue":"10104","key":"427_CR15","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747\u201357.","journal-title":"Lancet."},{"issue":"41","key":"427_CR16","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","volume":"38","author":"T Cuisset","year":"2017","unstructured":"Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070\u20138.","journal-title":"Eur Heart J."},{"issue":"10151","key":"427_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940\u20139.","journal-title":"Lancet."},{"issue":"1","key":"427_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40256-019-00361-5","volume":"20","author":"C Bruggmann","year":"2020","unstructured":"Bruggmann C, Iglesias JF, Gex-Fabry M, Fesselet R, Vogt P, Sadeghipour F, et al. Long-term quality of prescription for st-segment elevation myocardial infarction (STEMI) patients: a real world 1-year follow-up study. Am J Cardiovasc Drugs. 2020;20(1):105\u201315.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"22","key":"427_CR19","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","volume":"69","author":"TB Dondo","year":"2017","unstructured":"Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69(22):2710\u201320.","journal-title":"J Am Coll Cardiol."},{"issue":"354","key":"427_CR20","doi-asserted-by":"publisher","first-page":"i4801","DOI":"10.1136\/bmj.i4801","volume":"20","author":"E Puymirat","year":"2016","unstructured":"Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;20(354):i4801.","journal-title":"BMJ."},{"issue":"22","key":"427_CR21","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","volume":"97","author":"ACE Inhibitor Myocardial Infarction Collaborative Group","year":"1998","unstructured":"ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998;97(22):2202\u201312.","journal-title":"Circulation."},{"issue":"5","key":"427_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/CIRCOUTCOMES.109.919415","volume":"3","author":"AJ Bagnall","year":"2010","unstructured":"Bagnall AJ, Yan AT, Yan RT, Lee CH, Tan M, Baer C, et al. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes. 2010;3(5):530\u20137.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"5","key":"427_CR23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1161\/CIRCOUTCOMES.111.963959","volume":"5","author":"KA Somma","year":"2012","unstructured":"Somma KA, Bhatt DL, Fonarow GC, Cannon CP, Cox M, Laskey W, et al. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5(5):654\u201361.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"10","key":"427_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.amjcard.2012.08.028","volume":"110","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Messerli FH. Statin therapy for secondary prevention: is there a gender difference? Test for interaction in meta-analysis revisited. Am J Cardiol. 2012;110(10):1553\u20134.","journal-title":"Am J Cardiol."},{"issue":"6","key":"427_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/CIRCOUTCOMES.115.001987","volume":"8","author":"K Smolina","year":"2015","unstructured":"Smolina K, Ball L, Humphries KH, Khan N, Morgan SG. Sex disparities in post-acute myocardial infarction pharmacologic treatment initiation and adherence: problem for young women. Circ Cardiovasc Qual Outcomes. 2015;8(6):586\u201392.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"23","key":"427_CR26","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","volume":"32","author":"RC Becker","year":"2011","unstructured":"Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933\u201344.","journal-title":"Eur Heart J."},{"issue":"4","key":"427_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","volume":"10","author":"DG Karalis","year":"2016","unstructured":"Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, et al. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016;10(4):833\u201341.","journal-title":"J Clin Lipidol."},{"issue":"5","key":"427_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jcin.2017.10.015","volume":"11","author":"SY Lee","year":"2018","unstructured":"Lee SY, Hong MK, Palmerini T, Kim HS, Valgimigli M, Feres F, et al. Short-term versus long-term dual antiplatelet therapy after drug-eluting stent implantation in elderly patients: a meta-analysis of individual participant data from 6 randomized trials. JACC Cardiovasc Interv. 2018;11(5):435\u201343.","journal-title":"JACC Cardiovasc Interv."},{"issue":"8","key":"427_CR29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/hrt.2006.110197","volume":"93","author":"NK Choudhry","year":"2007","unstructured":"Choudhry NK, Levin R, Winkelmayer WC. Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart. 2007;93(8):945\u201351.","journal-title":"Heart."},{"issue":"23","key":"427_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/eurheartj\/ehu039","volume":"35","author":"MJ Zaman","year":"2014","unstructured":"Zaman MJ, Stirling S, Shepstone L, Ryding A, Flather M, Bachmann M, et al. The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: a cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Eur Heart J. 2014;35(23):1551\u20138.","journal-title":"Eur Heart J."},{"issue":"3","key":"427_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000475705","volume":"138","author":"TO Bergmeijer","year":"2017","unstructured":"Bergmeijer TO, Janssen PWA, van Oevelen M, van Rooijen D, Godschalk TC, Kelder JC, et al. Incidence and causes for early ticagrelor discontinuation: a \u201cReal-World\u201d Dutch Registry Experience. Cardiology. 2017;138(3):164\u20138.","journal-title":"Cardiology."},{"issue":"5 Suppl","key":"427_CR32","first-page":"S1","volume":"17","author":"CM White","year":"2011","unstructured":"White CM, Greene L. Summary of AHRQ\u2019s comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. J Manag Care Pharm. 2011;17(5 Suppl):S1\u201315.","journal-title":"J Manag Care Pharm."},{"issue":"7","key":"427_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3109\/10641963.2015.1026040","volume":"37","author":"A Sato","year":"2015","unstructured":"Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens. 2015;37(7):563\u20138.","journal-title":"Clin Exp Hypertens."},{"issue":"1","key":"427_CR34","doi-asserted-by":"publisher","first-page":"e005041","DOI":"10.1161\/CIRCOUTCOMES.118.005041","volume":"12","author":"AM Navar","year":"2019","unstructured":"Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, et al. Medication discontinuation in the IMPROVE-IT trial. Circ Cardiovasc Qual Outcomes. 2019;12(1):e005041.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"5","key":"427_CR35","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","volume":"7","author":"MY Wei","year":"2013","unstructured":"Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472\u201383.","journal-title":"J Clin Lipidol."},{"issue":"4","key":"427_CR36","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jacl.2016.04.010","volume":"10","author":"H Halava","year":"2016","unstructured":"Halava H, Huupponen R, Pentti J, Kivimaki M, Vahtera J. Predictors of first-year statin medication discontinuation: a cohort study. J Clin Lipidol. 2016;10(4):987\u201395.","journal-title":"J Clin Lipidol."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00427-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:15:51Z","timestamp":1628723751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00427-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00427-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"12 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by an unrestricted research grant from AstraZeneca Netherlands B.V.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P. Damman has received an unrestricted research grant from AstraZeneca Netherlands B.V. Niels PG Hoedemaker, Robbert J de Winter, Arnoud van \u2019t Hof, and Evelien Kolkman have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted with a waiver from the medical ethical committee of the Academic Medical Center in Amsterdam. According to Dutch law applicable at the time of the study period, written informed consent for the conduction of this registry study was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}